Trovagene expects additional evidence of clinical efficacy of onvansertib combined with chemoterapy in Acute Myeloid Leukemia

Preliminary efficacy data from Trovagene’s Phase 1b/2 study testing onvansertib in combination with standard-of-care chemotherapy in Acute Myeloid Leukemia (AML) is encouraging, in particular that it shows some complete and relatively durable responses, said lead investigator of the trial, Dr. Amer Zeidan.

Read more

Celgene Corporation and Agios Pharmaceuticals report first results from acute myeloid leukemia study

Celgene Corporation and Agios Pharmaceuticals have reported new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating investigational oral Idhifa (enasidenib) in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and an isocitrate dehydrogenase-2 (IDH2) mutation.

Read more